Rhythm AI has announced the signing of a research collaboration agreement with Biosense Webster. A press release outlines that the agreement grants Rhythm AI access to certain data from the Biosense Webster CARTO 3 system to support a multicentre clinical trial of its STAR Mapping system.
STAR Mapping is a new, AI driven mapping system developed using novel computer algorithms and has been design to identify the sources or drivers of atrial fibrillation (AF) from data acquired from the 3D Mapping equipment. Outcomes in a single centre study published in May 2019, according to a press release, demonstrated that 80% of patients treated in a single procedure using STAR Mapping were free of AF without the use of anti-arrhythmia drugs at an average of 18.5 months follow-up. The press release states that this compares very favourably to a study published in 2015, which demonstrated 48% of patients free form AF at 18 months follow-up using the standard mapping treatment.
Simon Hubbert, CEO of Rhythm AI says: “We are delighted to have reached agreement with Biosense Webster to collaborate on our forthcoming multicentre trial. STAR Mapping has demonstrated a significant improvement in outcomes in a single centre study and we look forward to further demonstrating the value of STAR in a UK multicentre trial with recruitment starting later this year.”